GFM
DAWN

GF Fund Management’s Day One Biopharmaceuticals DAWN Stock Holding History

GF Fund Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49.2K Buy
2,294
+277
+14% +$3.9K ﹤0.01% 400
2025
Q4 		$18.8K Sell
2,017
-187
-8% -$1.56K ﹤0.01% 511
2025
Q3 		$15.5K Sell
2,204
-378
-15% -$2.6K ﹤0.01% 520
2025
Q2 		$16.8K Hold
2,582
– – ﹤0.01% 519
2025
Q1 		$20.5K Buy
2,582
+465
+22% +$5.01K ﹤0.01% 501
2024
Q4 		$26.8K Buy
+2,117
New +$29.5K ﹤0.01% 446

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

GF Fund Management's DAWN Position: Q1 2026 in Review

GF Fund Management increased its Day One Biopharmaceuticals (DAWN) stake by 14% in Q1 2026, buying an estimated $3.9K and bringing the position to 2,294 shares worth $49.2K. The position accounts for ﹤0.01% of the portfolio, ranked #400.

GF Fund Management first reported a position in DAWN in Q4 2024 and has held it in 6 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • GF Fund Management held 2,294 shares of Day One Biopharmaceuticals worth $49.2K as of Q1 2026.
  • GF Fund Management bought 277 Day One Biopharmaceuticals shares in Q1 2026, an estimated $3.9K.
  • Day One Biopharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #400 holding.
  • GF Fund Management first reported a position in Day One Biopharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.